OncoMatch/Clinical Trials/NCT07104812
Impact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS)
Is NCT07104812 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Osilodrostat 1 MG for mild autonomous cortisol secretion.
Treatment: Osilodrostat 1 MG — The purpose of this study is to evaluate the safety and tolerability of 1 mg osilodrostat therapy in patients with mild autonomous cortisol secretion (MACS), and to determine the impact on 24h urine steroid metabolome and circadian cortisol/cortisone concentrations
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Prior therapy
Cannot have received: oral exogenous glucocorticoid therapy
Current use of oral exogenous glucocorticoid therapy
Cannot have received: opioid therapy
Exception: dose >20 MME/day
Current use of opioid therapy >20 MME/day
Cannot have received: injectable glucocorticoid
Use of injectable glucocorticoid within the last 6 weeks or anticipated glucocorticoid use during the study period.
Cannot have received: oral exogenous glucocorticoid therapy
Planned use of oral exogenous glucocorticoid therapy
Cannot have received: opioid therapy
Exception: dose >20 MME/day
Planned use of opioid therapy >20 MME/day
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic · Rochester, Minnesota
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07104812 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior oral exogenous glucocorticoid therapy, opioid therapy, injectable glucocorticoid disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify